论文部分内容阅读
目的探究原发性肝癌采用肝动脉化疗栓塞术(TACE)与贝伐单抗联合治疗的临床疗效,并分析治疗安全性。方法将2013年1月至2015年1月永城市人民医院收治并选取的符合研究标准的中晚期肝癌60例随机分组(TACE组、联用组,各30例),TACE组实施肝动脉化疗栓塞术治疗,联用组在TACE治疗前采用导管经动脉灌注4~6 mg/kg贝伐单抗,分别采用mRCIST(改良版实体瘤疗效评价标准)、生存质量卡氏评分评估两组术后临床收益率及生存质量情况,检测两组血清甲胎蛋白,并采用统计学SPSS20.0软件对比两组不良反应发生率、生存率。结果术后收益率、12个月生存率比较,联用组高于TACE组,差异有统计学意义(P<0.05)。两组术后血清甲胎蛋白含量比较,均较术前明显下降,且联用组改善情况优于TACE组,差异显著(P<0.05)。两组生存质量改善情况以及安全性比较,均无明显差异(P>0.05)。结论原发性肝癌采用肝动脉化疗栓塞术(TACE)与贝伐单抗联合治疗效果显著,能有效提高其生存率,具有一定的安全性,值得推广。
Objective To investigate the clinical efficacy of combined treatment of hepatic artery chemoembolization (TACE) and bevacizumab in patients with primary liver cancer and to analyze the safety of the treatment. Methods Totally 60 patients with advanced hepatocellular carcinoma (TACE group, 30 patients in each group) who were admitted to Yongcheng People’s Hospital from January 2013 to January 2015 were enrolled and selected. TACE group received hepatic artery chemoembolization The patients in combination group were treated with catheterization of 4 ~ 6 mg / kg bevacizumab by catheter before TACE treatment. The mRCIST (modified solid tumor efficacy evaluation criteria) and the Qoiety of quality of life Rate of return and quality of life, serum alpha-fetoprotein was detected in both groups, and SPSS 20.0 software was used to compare the incidence of adverse reactions and survival rate in the two groups. Results The postoperative rate of return and the 12-month survival rate were significantly higher in combined group than in TACE group (P <0.05). The postoperative serum alpha-fetoprotein levels in both groups were significantly lower than those before operation, and the improvement in combination group was better than TACE group (P <0.05). There was no significant difference between the two groups in quality of life improvement and safety (P> 0.05). Conclusion TACE combined with bevacizumab is effective in treating primary hepatic carcinoma, which can effectively improve the survival rate and have certain safety. It is worth to be popularized.